Search Result

Results for "

Control Peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Amino Acid Derivatives (1) Bacterial (2) Bcl-2 Family (3) Biochemical Assay Reagents (4) Bradykinin Receptor (1) Calcium Channel (2) CRFR (1) Deubiquitinase (1) Endogenous Metabolite (1) GCGR (4) GLP Receptor (1) HIV (2) iGluR (2) Mitophagy (1) MMP (2) NO Synthase (2) PKC (1) Protease Activated Receptor (PAR) (2) Proteasome (1) Src (1) STAT (1) TGF-β Receptor (1) Wnt (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (8) Endocrinology (2) Infection (3) Inflammation/Immunology (10) Metabolic Disease (4) Neurological Disease (14)
Oligonucleotides:	Polymers (1)

Inhibitors & Agonists

Peptides

Oligonucleotides

Targets Recommended: Natriuretic Peptide Receptor (NPR) Formyl Peptide Receptor (FPR) CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1513A

LL-37 scrambled peptide acetate	Bacterial	Infection
LL-37 scrambled peptide acetate is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide acetate can be used as a negative control of LL-37 peptide studies.

HY-P5023A

Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) TFA c(RADyK) TFA	Biochemical Assay Reagents	Cancer
Cyclo (ARG-ALA-ASP- (D-Tyr) -LYS) (TFA) (C (Radyk) (TFA)) is a control peptide for c(RGDyK) .

HY-103271

Bax inhibitor peptide, negative control	Bcl-2 Family	Cancer
Bax inhibitor peptide, negative control is a inhibitor of Bax. Bax inhibitor peptide, negative control inhibits Bax translocation to mitochondria and Bax-mediated apoptosis in vitro .

HY-P10169

Acetyl-Calpastatin(184-210)(human), Negative Control	Proteasome	Others
Acetyl-Calpastatin(184-210)(human), Negative Control is a control scramble peptide of Acetyl-Calpastatin(184-210)(human) (HY-P1081). Acetyl-Calpastatin(184-210)(human) is a potent, selective and reversible calpain inhibitor .

HY-P2039

Retrobradykinin	Bradykinin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Retrobradykinin has the reverse sequence of Bradykinin (HY-P0206). Retrobradykinin exhibits no kinin activity and can be used as a negative control for Bradykinin .

HY-P2547

Tyrosine Kinase Peptide 1	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

HY-P1513

LL-37 scrambled peptide	Bacterial	Infection
LL-37 scrambled peptide is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide can be used as a negative control of LL-37 peptide studies.

HY-P10099

STAT3-IN-21, cell-permeable, negative control	STAT	Cancer
STAT3-IN-21, cell-permeable, negative control, a peptide, is a negative control for Stat3 activity detection .

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P5023

Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) c(RADyK)	Biochemical Assay Reagents	Cancer
Cyclo (ARG-ALA-ASP- (D-Tyr) -LYS) (C (Radyk)) is a control peptide for c(RGDyK) .

HY-P3970C

KQFK	TGF-β Receptor	Others
KQFK is an inactive *control* of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .

HY-112668B

Retagliptin hydrochloride SP2086 hydrochloride	Others	Others
Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1) .

HY-P2004

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-P2004A

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-P1454B

Fz7-21S	Wnt	Cancer
Fz7-21S is a negative control of Fz7-21. Fz7-21 is a potent peptide antagonist of FZD7 receptors .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual *glucagon-like peptide-1 receptor/glucagon receptor* agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-P5325

Bid BH3 (80-99)	Bcl-2 Family	Others
Bid BH3 (80-99) is a biological active peptide. (BID is a pro-apoptotic member of the 'BH3-only' (BOPS) subset of the BCL-2 family of proteins that constitute a critical control point in apoptosis. Bid is the first of the BOPs reported to bind and activate Bcl-2, Bax, and Bak. Bid serves as a death-inducing ligand that moves from the cytosol to the mitochondrial membrane to inactivate Bcl-2 or to activate Bax.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P3842

Protein Kinase C (661-671)	PKC	Cancer
Protein Kinase C (661-671) is a fragment peptide of β1 subspecies of protein kinase C (PKC). PKC plays a role in cellular growth control and tumor promotion .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of *glucagon-like peptide-1 (GLP-1)* and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of *glucagon-like peptide-1 (GLP-1)* and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P5327

r8 Bid BH3	Bcl-2 Family	Others
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)

HY-E70128

Leucyl aminopeptidase	Others	Others
Leucyl aminopeptidase is a metallopeptidase that cleave N-terminal residues from proteins and peptides. Leucyl aminopeptidase serves as transcriptional repressors to control pyrimidine, alginate and cholera toxin biosynthesis, as well as mediate site-specific recombination events in plasmids and phages .

HY-P10058

cpm-1285m	Biochemical Assay Reagents	Cancer
cpm-1285m is a cell-permeable mutated peptide analogue of cpm-1285 (Bcl-2 inhibitory peptide). cpm-1285m contains a single substitution of alanine for Leu-151, and exhibits a decrease in Bcl-2 binding affinity with a reduction in IC₅₀ of ∼15-fold. cpm-1285m can be used as a control of cpm-1285 .

HY-P1310

VKGILS-NH2 1 Publications Verification	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells .

HY-P1310A

VKGILS-NH2 TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells .

HY-114174

Fmoc-Ala-Glu-Asn-Lys-NH2	Amyloid-β	Neurological Disease
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing .

HY-P4114

TAT-NSF700scr	HIV	Others
TAT-NSF700scr consists the intact TAT domain and glycine linker, followed by the NSF amino acids in a random order. TAT-NSF700scr is used as a control peptide that does not inhibit SNAREmediated exocytosis .

HY-117912

TRC210258	Others	Cardiovascular Disease
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .

HY-P3882

Fmoc-Ala-Glu-Gln-Lys-NH2	Amino Acid Derivatives	Neurological Disease
Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein .

HY-B2247A

PLGA (75:25) poly(lactic-co-glycolic acid) (75:25)	Biochemical Assay Reagents	Others
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the **control peptide** of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-P1075

CALP3 2 Publications Verification	Calcium Channel	Neurological Disease Cancer
CALP3, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-P1075A

CALP3 TFA	Calcium Channel	Neurological Disease Cancer
CALP3 TFA, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 TFA can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P10416

Q14 Q14 Peptide	Deubiquitinase Mitophagy	Others Neurological Disease
Q14 is a polypeptide derived from the USP30 (ubiquitin specific peptidase 30) transmembrane (TM) domain with the ability to inhibit the deubiquitination activity of USP30 (IC₅₀=57.2 nM). Q14 reduces USP30 activity by inhibiting the interaction between the USP30 transmembrane domain and its catalytic domain. Q14 peptide contains the LC3 interaction region (LIR) motif, which enables it to bind to the LC3 and accelerate the formation of autophagosomes, thereby promoting mitophagy. Q14 can be used in the study of neurodegenerative diseases as well as mitochondrial quality control and cell metabolism .

Cat. No.	Product Name	Target	Research Area

HY-P1398

Compstatin control peptide	Peptides	Inflammation/Immunology
Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P1383A

*Rac1 Inhibitor F56, control* peptide TFA**	Peptides	Others
Rac1 Inhibitor F56, control peptide TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide TFA contains a Trp ⁵⁶ to Phe ⁵⁶ mutation. Rac1 Inhibitor F56, control peptide TFA has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs) .

HY-P3708

TRAF6 control peptide	Peptides	Others
TRAF6 control peptide is a control peptide for TRAF6 .

HY-P10166

MLCK Peptide, control	Peptides	Others
MLCK Peptide, control is a myosin light-chain kinase. Adding MLCK peptide to permeabilized L15 cells dramatically decreased IICR. MLCK peptide caused a reduction in the extent of IICR with no change in the affinity of IP3 for the IP3R .

HY-103271

Bax inhibitor peptide, negative control	Bcl-2 Family	Cancer
Bax inhibitor peptide, negative control is a inhibitor of Bax. Bax inhibitor peptide, negative control inhibits Bax translocation to mitochondria and Bax-mediated apoptosis in vitro .

HY-P1398A

*Compstatin control* peptide TFA**	Peptides	Inflammation/Immunology
Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P10088

Mouse TREM-1 SCHOOL peptide, control	Peptides	Inflammation/Immunology Cancer
Mouse TREM-1 SCHOOL peptide, control is a negative control of Mouse TREM-1 SCHOOL peptide .

HY-P0301

*SLLK, Control* Peptide for TSP1 Inhibitor**	Peptides	Cancer
SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).

HY-P5119

*Tat-peptide* control 168-189**	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron .

HY-P1383

Rac1 Inhibitor F56, control peptide	Peptides	Others
Rac1 Inhibitor F56, control peptide is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide contains a Trp ⁵⁶ to Phe ⁵⁶ mutation. Rac1 Inhibitor F56, control peptide has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs) .

HY-P0301A

*SLLK, Control* Peptide for TSP1 Inhibitor(TFA)**	Peptides	Cancer
SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

HY-P5119A

*Tat-peptide* control 168-189 TFA**	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron .

HY-P10168

11R-CaN-CON	Peptides	Others
11R-CaN-CON is a control inactive peptide and can be used as a negative control for 11R-CaN-AID (HY-P10167) .

HY-P10471B

Ala-MPSD	Peptides	Others
Ala-MPSD is a control peptide for MPSD (HY-P10471). In Ala-MPSD, the four serine residues of MPSD are substituted by alanines .

HY-P10471C

Ala-MPSD TFA	Peptides	Others
Ala-MPSD TFA is a control peptide for MPSD (HY-P10471). In Ala-MPSD TFA, the four serine residues of MPSD are substituted by alanines .

HY-P5986

mSIRK (L9A)	Peptides	Others
mSIRK (L9A) is a cell-permeable, N-myristoylated G-Protein Binding Peptide (mSIRK). mSIRK (L9A) contains a single point mutation (Leu9 to Ala). mSIRK (L9A) cannot enhance ERK1/2 phosphorylation. mSIRK (L9A) can be used as a control peptide .

HY-P2670

SN50M	Peptides	Others
SN50M, a mutant peptide of SN50 (HY-P0151), is a cell membrane-permeable inactive control peptide .

HY-P10169

Acetyl-Calpastatin(184-210)(human), Negative Control	Proteasome	Others
Acetyl-Calpastatin(184-210)(human), Negative Control is a control scramble peptide of Acetyl-Calpastatin(184-210)(human) (HY-P1081). Acetyl-Calpastatin(184-210)(human) is a potent, selective and reversible calpain inhibitor .

HY-P1513A

LL-37 scrambled peptide acetate	Bacterial	Infection
LL-37 scrambled peptide acetate is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide acetate can be used as a negative control of LL-37 peptide studies.

HY-P3460

TDSRCVIGLYHPPLQVY	Peptides	Cardiovascular Disease Neurological Disease Inflammation/Immunology
TDSRCVIGLYHPPLQVY is a disordered control peptide. TDSRCVIGLYHPPLQVY is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order .

HY-P3460A

TDSRCVIGLYHPPLQVY TFA	Peptides	Cardiovascular Disease Neurological Disease Inflammation/Immunology
TDSRCVIGLYHPPLQVY TFA is a disordered control peptide. TDSRCVIGLYHPPLQVY TFA is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order .

HY-P1402

[Glu27]-PKC (19-36)	Peptides	Others
[Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .

HY-P10116

APTSTAT3-9R, scrambled APTscr-9R	Peptides	Others
APTSTAT3-9R, scrambled (APTscr-9R) is a control peptide that forms a structure similar to that of APTSTAT3-9R but possesses a scrambled sequence in the target-binding region .

HY-P10101

APT STAT3, scrambled APTscr	Peptides	Others
APT STAT3, scrambled (APTscr), a control peptide of STAT3-specific aptide (APT_STAT3), does not bind STAT3. APT STAT3, scrambled contains the same trpzip scaffold but with a scrambled sequence in the target-binding site .

HY-P10096

STAT3-IN-22, negative control PYLKTK	Peptides	Others
STAT3-IN-22, negative control (PYLKTK) is a peptide that serves as a control peptide for phosphotyrosine .

HY-P2039

Retrobradykinin	Bradykinin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Retrobradykinin has the reverse sequence of Bradykinin (HY-P0206). Retrobradykinin exhibits no kinin activity and can be used as a negative control for Bradykinin .

HY-P4124

Pepinh-Control	Peptides	Others
Pepinh-Control is a negative control peptide .

HY-P1391

ZIP(Scrambled)	Peptides	Others
ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP) .

HY-P10737

CGGK	Peptides	Neurological Disease
CGGK is a control peptide of CAQK peptide (HY-P10216) .

HY-P1391A

ZIP(Scrambled) TFA	Peptides	Others
ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP) .

HY-P2547

Tyrosine Kinase Peptide 1	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

HY-P5035

Cyclo(Gly-Arg-Gly-Glu-Ser-Pro) c(GRGESP)	Peptides	Others
Cyclo(Gly-Arg-Gly-Glu-Ser-Pro) (c(GRGESP)) is a peptide that serves as a control peptide for the inhibitory peptide cyclo-GRGDSP .

HY-P5384

sgp91 ds-tat	Peptides	Others
sgp91 ds-tat is a biological active peptide. (This is a scrambled control peptide for gp91 ds-tat.)

HY-P5400

OVA (257-264), scrambled	Peptides	Others
OVA (257-264), scrambled is a biological active peptide. (Out-of-order control peptide of HY-P1489)

HY-P1513

LL-37 scrambled peptide	Bacterial	Infection
LL-37 scrambled peptide is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide can be used as a negative control of LL-37 peptide studies.

HY-129067

Brain natriuretic peptide BNP (1-32), human	Peptides	Cardiovascular Disease
Brain natriuretic peptide inhibits angiotensin II-induced blood pressure. Brain natriuretic peptide can be used in the control of blood pressure .

HY-P2248

ELA-14 negative control	Peptides	Others
ELA-14 negative control, a peptide, is inactive. ELA-14 negative control is a negative control for ELA-14 .

HY-P10099

STAT3-IN-21, cell-permeable, negative control	STAT	Cancer
STAT3-IN-21, cell-permeable, negative control, a peptide, is a negative control for Stat3 activity detection .

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P3720

YEQLRNSRA	Peptides	Cancer
YEQLRNSRA is a MycC Peptide. MycC Peptide is encoded by c-myc proto-oncogene, the c-myc oncogene has been implicated in malignant progression in a variety of human tumors. MycC Peptide regulates fundamental cellular processes like growth control, metabolism, proliferation, differentiation, and apoptosis .

HY-P1897

Fibronectin Active Fragment Control	Peptides	Inflammation/Immunology
Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins .

HY-P10660

CMV pp65 (415-429)	Peptides	Infection Inflammation/Immunology
CMV pp65 (415-429) is a CEF control peptide that is derived from the Cytomegalovirus (CMV) .

HY-P2360

G12 Ras 5-17	Peptides	Others
G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12) .

HY-P3211B

Nangibotide scrambled peptide 1 Publications Verification LR12-scr	Peptides	Inflammation/Immunology
Nangibotide scrambled peptide (LR12-scr) is a scrambled control peptide composed of the same amino acids from LR12 (Nangibotide; HY-P3211) but in a random sequence (YQDVELCETGED) .

HY-P4232

H-Gly-Arg-Ala-Asp-Ser-Pro-OH	Peptides	Others
H-Gly-Arg-Ala-Asp-Ser-Pro-OH (GRADSP) is a negative control peptide of GRGDdSP .

HY-P5023

Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) c(RADyK)	Biochemical Assay Reagents	Cancer
Cyclo (ARG-ALA-ASP- (D-Tyr) -LYS) (C (Radyk)) is a control peptide for c(RGDyK) .

HY-P2360A

G12 TFA Ras 5-17 TFA	Peptides	Others
G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12) .

HY-P0309

Arg-Gly-Glu-Ser	Peptides	Cancer
Arg-Gly-Glu-Ser is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

HY-P1311

RLLFT-NH2	Peptides	Others
RLLFT-NH2 is a reversed amino acid sequence negative control peptide for TFLLR-NH2 .

HY-P0309A

Arg-Gly-Glu-Ser TFA	Peptides	Others
Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

Cat. No.	Product Name		Classification

HY-B2247A

PLGA (75:25) poly(lactic-co-glycolic acid) (75:25)		Polymers
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: